G1T30

**G1T30** is a small molecule inhibitor targeting cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6). It was initially developed by G1 Therapeutics for oncology applications, specifically for neoplasms. G1T30 acts by inhibiting CDK4 and CDK6 activity, both key regulators of cell cycle progression from G1 to S phase, thereby blocking cancer cell proliferation. It is related to the metabolism of lerociclib (GB491), serving as its main metabolite detected in pharmacokinetic studies, with serum concentrations measured in clinical research. The global highest R&D status is currently pending, with preclinical stage indicated. No major brand or trade names are reported for G1T30; it is primarily referenced as a code name in preclinical research contexts[1][3].